Every material Form 8-K AMARIN CORP PLC\UK has filed with the SEC since April 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Amarin reported third-quarter 2026 total net revenue of $39.6 million, down 20% from $49.7 million a year earlier, driven by a 30% decline in U.S. VASCEPA sales. The company reported net income of $245 thousand, compared with a net loss of $7.7 million in the same quarter of 2025, and said it is working with Barclays as its exclusive financial advisor on efforts to maximize shareholder value.
Q3 2026 total net revenue was $39.6 million, down 20% from $49.7 million; U.S. product revenue fell 30% to $28.5 million.
Q3 2026 net income was $245 thousand, versus a net loss of $7.7 million in Q3 2025; nine-month net loss narrowed to $17.9 million from $37.6 million.
Cash, cash equivalents and short-term investments were $323.4 million at September 30, 2026, and the company reported no debt.
Amarin is working with Barclays, its exclusive financial advisor, on efforts to maximize shareholder value.
Amarin reported second-quarter 2026 results with total net revenue of $42.2 million, down 42% from $72.7 million a year earlier, mainly because Q2 2025 included a $25 million up front payment from the Recordati agreement. Net loss narrowed to $7.7 million from $14.1 million, and operating expenses fell 59% to $27.0 million as the company completed a $70 million annual cost savings initiative.
Total net revenue was $42.2 million in Q2 2026, down 42% from $72.7 million in Q2 2025; the Q2 2025 figure included a $25 million up front Recordati payment.
Net loss was $7.7 million, or $0.02 per share, compared with a net loss of $14.1 million, or $0.03 per share, in Q2 2025.
Operating expenses fell $39.3 million, or 59%, to $27.0 million; excluding restructuring charges, they fell 38%.
Cash was $314.6 million as of June 30, 2026, and the company remained debt free.
Amarin reported first-quarter 2026 results, with total net revenue up 7% to $45.1 million from $42.0 million a year earlier, led by higher licensing and royalty income and new rest-of-world product sales. Operating expenses fell 31% to $29.1 million, narrowing the operating loss to $11.3 million and the net loss to $10.5 million, and the company said it generated positive cash flow for the second consecutive quarter. Amarin reiterated its expectation of positive cash flow for full year 2026.
Total net revenue was $45.1 million versus $42.0 million in Q1 2025; licensing and royalty revenue rose 84%.
Operating loss narrowed to $11.3 million from $16.8 million; operating expenses fell 31% to $29.1 million.
Net loss was $10.5 million, or $(0.03) per share, versus $15.7 million, or $(0.04) per share, a year earlier.
Cash and investments were $307.8 million as of March 31, 2026, and the company reported no debt.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AMARIN CORP PLC\UK filing is on SEC EDGAR ↗. 8-K briefs of other companies →